HIM
RARE icon

Hillsdale Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Hillsdale Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,700
Closed -$877K – 638
2021
Q1 		$877K Hold
7,700
– – 0.07% 266
2020
Q4 		$1.07M Sell
7,700
-3,500
-31% -$415K 0.1% 206
2020
Q3 		$921K Buy
+11,200
New +$928K 0.09% 195

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hillsdale Investment Management's RARE Position: Q2 2021 in Review

Hillsdale Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 7,700 shares — an estimated $877K sold.

Hillsdale Investment Management first reported a position in RARE in Q3 2020 and held it in 3 quarters. The position peaked at $1.07M in Q4 2020. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

  • Hillsdale Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Hillsdale Investment Management sold 7,700 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $877K.
  • Hillsdale Investment Management first reported a position in Ultragenyx Pharmaceutical in Q3 2020 and held it in 3 quarters.
  • Hillsdale Investment Management's Ultragenyx Pharmaceutical position peaked at $1.07M in Q4 2020.
  • 242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Hillsdale Investment Management's 13F filing for Q2 2021, filed 29 Jul 2021.